Organogenesis (NASDAQ: ORGO)
Organogenesis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Organogenesis Company Info
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
News & Analysis
Why Organogenesis Holding Stock Plummeted by 18% Today
A double miss put the wound care specialist's shares on the sick list.
Why Shares of Organogenesis Holdings Are Up Thursday
The company said it learned that its products will again be covered by three Medicare Administrative Contractors.
Why Shares of Organogenesis Holdings Are Dropping Thursday
The advanced wound care company announced second-quarter earnings.
Why Shares of Organogenesis Climbed Wednesday
A competitor's recall could help the advanced wound care company gain market share.
Why Shares of Organogenesis Holdings Jumped Thursday
The company, which specializes in wound care solutions, released first-quarter earnings.
Why Organogenesis Stock Is Tumbling Today
It didn't make as much money in the second quarter as investors were hoping.
Is This Healthcare Stock a Value Trap?
Don't be blinded by its attractive valuation.
Why Organogenesis Holdings Stock Blasted 21% Higher Today
The company delivered quite an upside surprise with its fourth-quarter earnings release.
Valuation
Earnings Transcripts
Organogenesis (ORGO) Q4 2024 Earnings Call Transcript
ORGO earnings call for the period ending December 31, 2024.
Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
ORGO earnings call for the period ending September 30, 2024.
Organogenesis (ORGO) Q2 2024 Earnings Call Transcript
ORGO earnings call for the period ending June 30, 2024.
Organogenesis (ORGO) Q1 2024 Earnings Call Transcript
ORGO earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.